About 30 giants in the pharmaceutical industry warn, by letter, Brussels for the possibility of “exit investors” in the midst of commercial tensions
The presidents of about 30 large pharmaceuticals sent a warning letter to Brussels, demanding certain conditions to prevent investors from leaving the US in a climate of trade war.
In a letter addressed on April 11th to European Commission President Ursula von der Layen, the heads of 32, large and medium -sized pharmaceutical companies, promise to “increase” the share of the European market – which today represents 22.7% in worldwide sales.
Without them, “in three months from today, scheduled investments of 16.5 billion euros could be transferred outside Europe,” warned NOVO NORDISK, PFIizer, Eli Lilly, Roche, Sanofi, Merck, GSK and Servier presidents in the letter that was released by many media and which has come to know today.
Companies are calling for a competitive European market “that attracts, correctly evaluates and rewards innovation”, considering that “continued commercial tensions will further accelerate the reduction in investment in research and growth and production in the European Union”.
As they say, this must be done by revising the pricing policy of drugs in Europe, which is less favorable than that applied to the United States, and a revision of the regulatory framework.
The procedure for clinical trials carried out in several countries must be shortened and the European Agency’s resources should be increased to enable innovative treatments, according to the signatories.
They also ask Brussels to “suspend and review” the directive aimed at improving the treatment of sewage before being dismissed in the environment, “in order to prevent disproportionate burdens” for the sector.
Pharmaceuticals are currently exempt from the customs duties imposed by Washington. However, several pharmaceutical groups have recently announced investments to boost production in the United States: Eli Lilly $ 27 billion, $ 55 billion in the next 4 years by Johnson & Johnson. Merck inaugurated vaccines in North Carolina, a $ 1 billion project.
The Swiss pharmaceutical giant Novartis announced on Thursday that it will invest $ 23 billion in the United States for five years to produce the basic drugs intended for American patients.
Source: Skai
I am Janice Wiggins, and I am an author at News Bulletin 247, and I mostly cover economy news. I have a lot of experience in this field, and I know how to get the information that people need. I am a very reliable source, and I always make sure that my readers can trust me.
